Table of contents

Jim Dillon New CEO at BiVACOR | Experienced Device Executive

Jim Dillon

BiVACOR, Inc., a clinical-stage medical technology company developing a total artificial heart (TAH), today announced that Jim Dillon has been named chief executive officer and a member of its board of directors.

Jim Dillon is an experienced medical device executive whose career focus in heart failure has included developing cardiovascular therapies to enable native heart recovery, reducing the size of a patient’s myocardial infarction, repairing adult and congenital cardiac defects, and volume management for acutely decompensated congestive heart failure patients.

“Jim’s leadership style, combined with his experience in building high-performance teams as well as expertise in the heart failure field, makes him the ideal person to lead BiVACOR,” stated Raymond W. Cohen, Chairman of the Board of BiVACOR. “We are thrilled to have him join as CEO.”

Over his multi-decade career, Jim Dillon has held a series of corporate strategic and sales leadership positions as a key contributor to multiple successful medical device companies. Prior to his recent role as CEO of clinical-stage private company BioVentrix, he held senior executive sales and marketing positions with Abiomed, TherOx, and InfraReDx.

“It’s a privilege to lead the BiVACOR team at a pivotal time in the company’s history,” said Mr. Dillon. “A Total Artificial Heart (TAH) is unique in its complexity and importance as an advanced treatment option for end-stage biventricular heart failure patients. The BiVACOR TAH device has the potential to truly revolutionize the field.”

In late November, BiVACOR announced that the U.S. Food and Drug Administration approved an investigational device exemption allowing the company to conduct a first-in-human clinical feasibility study of the BiVACOR TAH. The study will evaluate the safety and feasibility of the TAH as a bridge to heart transplant in the treatment of subjects with biventricular heart failure. Initially, three patients will be enrolled at The Texas Heart Institute in Houston. The study is anticipated to commence in the first half of 2024.

Other Executives In the News

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Executives on the Move

Dr. Val Kolesnitchenko brings extensive ophthalmology experience in clinical practice and industry to new therapeutics for the aging eye.
These strategic appointments signify a significant milestone for BRIJ Medical as they usher in a new era of post-surgical and trauma incision care with proven technologies that minimize wound complications and scarring.
Dr. Eckhard von Keutz has extensive experience in designing and conducting preclinical/toxicological studies, and toxicological risk assessment and management.
David Kroekel has more than 35 years of experience in medical device, combination product operations, and product development.
Dr. Konstantin Kousoulas, a leading virologist will work to further Rational Vaccines core mission of eradicating the world of the herpes simplex virus. "Dr. Kousoulas...

By using this website you agree to accept Medical Device News Magazine Privacy Policy